Vividion Therapeutics has dosed the first subject in a Phase I trial of an oral inhibitor, VVD-159642, aimed at treating rat sarcoma (RAS)-driven cancers.
This trial aims to assess VVD-159642’s tolerability, preliminary anti-tumour activity, pharmacokinetics, and safety as a monotherapy and in conjunction with trametinib or sotorasib in individuals with advanced solid tumours.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to the company, the therapy is the fourth clinical-stage programme derived from its chemoproteomics discovery platform.
It is designed to block the signalling pathway of the RAS-phosphatidylinositol 3-kinase alpha (PI3Kα), which plays an important role in the development and progression of solid tumours.
In addition to VVD-159642, the company is conducting other Phase I trials assessing an oral, Kelch-like, ECH-associated protein 1 (KEAP1) activator, as well as an oral signal transducer and activator of transcription 3 (STAT3) focusing on solid and haematologic malignancies.
Vividion Therapeutics’ chief medical officer Jenna Goldberg said: “Despite being a major driver in approximately 20% of cancers, the RAS gene has proven exceptionally difficult to target with drugs, largely due to its essential role in the RAS-PI3Kα signalling pathway, which is vital for healthy cell function.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“In addition to providing a more tolerable alternative to current therapies, we believe that VVD-159642 has the potential to treat a broad patient population, including in both RAS-mutant and HER2-overexpressed tumours, and may deliver increased efficacy in combination with other RAS/mitogen-activated protein kinase (MAPK) pathway inhibitors.”
As a ‘wholly owned’ Bayer subsidiary, Vividion uses discovery technologies to address ‘undruggable’ targets using therapeutics for cancers and immune disorders.
In February 2024, the company initiated subject dosing in a Phase I trial of VVD-130850, an investigational oral STAT3 inhibitor aimed at treating advanced solid and haematologic tumours.
